Titan Non Current Liabilities Other from 2010 to 2025

TTNP Stock  USD 3.68  0.19  4.91%   
Titan Pharmaceuticals Non Current Liabilities Other yearly trend continues to be relatively stable with very little volatility. Non Current Liabilities Other is likely to grow to about 1 M this year. During the period from 2010 to 2025, Titan Pharmaceuticals Non Current Liabilities Other destribution of quarterly values had range of 1.3 M from its regression line and mean deviation of  486,698. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2010-12-31
Previous Quarter
557.1 K
Current Value
M
Quarterly Volatility
541.1 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Titan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Titan Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.8 K, Interest Expense of 31.7 K or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 36.84, Dividend Yield of 0.0015 or PTB Ratio of 1.14. Titan financial statements analysis is a perfect complement when working with Titan Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Titan Pharmaceuticals Correlation against competitors.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Latest Titan Pharmaceuticals' Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Titan Pharmaceuticals over the last few years. It is Titan Pharmaceuticals' Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Titan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

Titan Non Current Liabilities Other Regression Statistics

Arithmetic Mean1,043,735
Geometric Mean924,008
Coefficient Of Variation51.85
Mean Deviation486,698
Median619,000
Standard Deviation541,127
Sample Variance292.8B
Range1.3M
R-Value(0.80)
Mean Square Error112B
R-Squared0.64
Significance0.0002
Slope(91,138)
Total Sum of Squares4.4T

Titan Non Current Liabilities Other History

2025M
2024557.1 K
2016619 K
20141.4 M

About Titan Pharmaceuticals Financial Statements

Titan Pharmaceuticals shareholders use historical fundamental indicators, such as Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Although Titan Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Titan Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Titan Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Non Current Liabilities Other557.1 KM

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.